PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 12 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

17 April 2026

  1. (diff | hist) 09:06 Loss on drying 4,874 ±0 TirzTaxonomist (talk | contribs) expand §Why the distinction from water matters [rollback]
  2. (diff | hist) 07:24 Blind sampling 8,193 ±0 BatchNumberBede (talk | contribs) ce per PP:MOS [rollback]
  3. (diff | hist) 00:59 Sigma-Aldrich (Shanghai) Trading 18,641 ±0 UnderfillUna (talk | contribs) expand §Ordering and availability [rollback]

16 April 2026

  1. (diff | hist) 22:53 Receptor bias 4,477 ±0 Chromatokid (talk | contribs) rm the causal claim about appetite — the cited work is associative [rollback]
  2. (diff | hist) 18:47 High-performance liquid chromatography 7,231 ±0 GradientGus (talk | contribs) convert the method-comparison paragraph to a table [rollback]
  3. (diff | hist) 14:05 Talk:Amylin receptor agonist 611 +196 ReceptorRhoda (talk | contribs) /* Calcitonin receptor cross-activity */ reply
  4. (diff | hist) 14:05 Talk:SURPASS trial programme 748 +104 EndpointEnid (talk | contribs) /* Active-comparator CVOT */ reply
  5. (diff | hist) m 12:37 International nonproprietary name 4,356 ±0 CuriousCallum (talk | contribs) ce per PP:MOS [rollback]
  6. (diff | hist) 10:30 Talk:Amylin receptor agonist 400 +273 AmylinAmos (talk | contribs) /* Calcitonin receptor cross-activity */ new section
  7. (diff | hist) 10:30 Talk:SURPASS trial programme 537 +159 SelectTrialSam (talk | contribs) /* Active-comparator CVOT */ new section
  8. (diff | hist) 09:20 Talk:Global access disparity 822 +170 BalanceBirdie (talk | contribs) /* Framing of the access argument */ reply
  9. (diff | hist) 09:17 Talk:Peptide stability table 1,096 +206 StabilityStig (talk | contribs) /* RfC: should the table give a −20 °C default for research powders? */ reply
  10. (diff | hist) m b 07:51 Trial data comparison 7,303 ±0 CiteBot (talk | contribs) bot: sort category members [rollback]
  11. (diff | hist) 07:20 TRIUMPH trial programme 4,703 ±0 DrTitration (talk | contribs) flag the pooled analysis as post hoc [rollback]
  12. (diff | hist) 05:25 Counterfeit peptide 5,488 ±0 SchematicScout (talk | contribs) add the note that a purity figure without water and counterion is not a mass [rollback]

15 April 2026

  1. (diff | hist) 23:51 Temperature excursion 24,964 ±0 StopperingSteff (talk | contribs) give the closure integrity test by name [rollback]
  2. (diff | hist) 23:41 Insulin syringe unit conversion 6,290 ±0 DeletionDeb (talk | contribs) expand §The converter [rollback]
  3. (diff | hist) 23:11 CagriSema 5,687 ±0 CDMO_Caradoc (talk | contribs) state the substitution in one-letter code as well, per PP:MOS [rollback]
  4. (diff | hist) 18:28 Purity claim inflation 5,660 ±0 ReportReaderRilla (talk | contribs) give the fields a compendially-complete certificate would carry [rollback]
  5. (diff | hist) 15:44 Talk:Peptide stability table 885 +304 AnalyticalAnnie (talk | contribs) /* RfC: should the table give a −20 °C default for research powders? */ reply
  6. (diff | hist) 14:48 Talk:Glucose-dependent insulinotropic polypeptide 611 +179 Ref_Desk_Ron (talk | contribs) /* GIP-incompetence: sourcing and terminology */ reply
  7. (diff | hist) 14:30 Incretin effect 7,358 ±0 FiveOhThreeA (talk | contribs) state that the receptor is a class B G-protein-coupled receptor [rollback]
  8. (diff | hist) 14:10 Talk:Loss on drying 748 +106 LyophilLena (talk | contribs) /* High figures are not defects */ reply
  9. (diff | hist) 13:15 Talk:Global access disparity 611 +145 NPOV_Nadia (talk | contribs) /* Framing of the access argument */ reply
  10. (diff | hist) 13:02 Talk:Peptide stability table 674 +492 RfC_Rasmus (talk | contribs) /* RfC: should the table give a −20 °C default for research powders? */ new section
  11. (diff | hist) 10:40 Talk:Loss on drying 537 +157 BalanceBirdie (talk | contribs) /* High figures are not defects */ new section
  12. (diff | hist) 10:22 Talk:Glucose-dependent insulinotropic polypeptide 400 +241 Chromatokid (talk | contribs) /* GIP-incompetence: sourcing and terminology */ new section
  13. (diff | hist) m b 10:21 AmbioPharm 16,953 +461 ArchiveBot (talk | contribs) bot: normalise citation format [rollback]
  14. (diff | hist) 09:40 Talk:Global access disparity 400 +200 DisparityDagny (talk | contribs) /* Framing of the access argument */ new section
  15. (diff | hist) 09:07 Talk:Beyond-use date 1,370 +287 EndotoxinEd (talk | contribs) /* Community dating practice: describe or omit? */ reply
  16. (diff | hist) 09:00 Talk:Arcuate nucleus 959 +116 PrimarySrcPatia (talk | contribs) /* How much animal work should be cited as though it were human? */ reply
  17. (diff | hist) 04:22 Amino acid analysis 4,943 ±0 TechnicianTeal (talk | contribs) expand §Systematic errors [rollback]
  18. (diff | hist) 03:03 Weight regain after discontinuation 4,670 ±0 ClinicCorrespondent (talk | contribs) attribute the boxed-warning statement to the regulator that issued it [rollback]

14 April 2026

  1. (diff | hist) 21:02 Syringe dead space 20,968 +109 DrTitration (talk | contribs) the example withdrew more than the syringe holds; corrected [rollback]
  2. (diff | hist) 15:25 Talk:Arcuate nucleus 748 +215 ArcuateArt (talk | contribs) /* How much animal work should be cited as though it were human? */ reply
  3. (diff | hist) m 14:38 Fasting insulin 4,198 ±0 LabRangeLindy (talk | contribs) British spelling per PP:MOS [rollback]
  4. (diff | hist) 14:20 Talk:Beyond-use date 1,159 +269 HarmReductionHen (talk | contribs) /* Community dating practice: describe or omit? */ reply
  5. (diff | hist) 14:05 Talk:Contract development and manufacturing organisation 748 +113 DisclosureDido (talk | contribs) /* Checkable claims */ reply
  6. (diff | hist) 13:25 Talk:Liquid chromatography-mass spectrometry 611 +140 MassSpecMarv (talk | contribs) /* Purity by LC-MS is ambiguous */ reply
  7. (diff | hist) m 12:14 PeptideMeter 4,925 ±0 OrphanPageOrin (talk | contribs) clarify that a signature on a certificate is a release, not a verification [rollback]
  8. (diff | hist) m 12:03 PolyPeptide Group (Hangzhou) 18,363 ±0 Compounding_Cate (talk | contribs) add the transit window each regional warehouse serves [rollback]
  9. (diff | hist) 11:40 Talk:Arcuate nucleus 537 +125 PrimarySrcPatia (talk | contribs) /* How much animal work should be cited as though it were human? */ new section
  10. (diff | hist) 10:52 Talk:Beyond-use date 948 +337 ScopeSeverin (talk | contribs) /* Community dating practice: describe or omit? */ new section
  11. (diff | hist) 10:30 Talk:Contract development and manufacturing organisation 537 +262 VerifyVesna (talk | contribs) /* Checkable claims */ new section
  12. (diff | hist) 09:50 Talk:Liquid chromatography-mass spectrometry 400 +135 Areapercent_Ayo (talk | contribs) /* Purity by LC-MS is ambiguous */ new section
  13. (diff | hist) m b 07:41 Tirzepatide 8,037 ±0 CategoryBot (talk | contribs) bot: repair redlinked category [rollback]

13 April 2026

  1. (diff | hist) 18:31 Shanghai ERP Biotechnology 14,637 ±0 VerifyVesna (talk | contribs) expand the product-scope row in the infobox [rollback]
  2. (diff | hist) m b 16:01 STEP trial programme 5,534 ±0 CategoryBot (talk | contribs) bot: flag bare reference [rollback]
  3. (diff | hist) 14:45 Talk:Test report forgery 748 +69 ForgeryFinder (talk | contribs) /* Absence of signals establishes nothing */ reply
  4. (diff | hist) 14:05 Talk:Adverse effects of GLP-1 receptor agonists 748 +96 HedgeHedda (talk | contribs) /* Precautionary contraindication */ reply
  5. (diff | hist) 11:42 Research use only 7,990 ±0 DMF_Dermot (talk | contribs) add the customs-detention point with its source [rollback]
  6. (diff | hist) 11:20 Talk:Test report forgery 537 +166 ReportReaderRilla (talk | contribs) /* Absence of signals establishes nothing */ new section
  7. (diff | hist) 10:30 Talk:Adverse effects of GLP-1 receptor agonists 537 +208 MTC_Marisol (talk | contribs) /* Precautionary contraindication */ new section
  8. (diff | hist) 07:58 Multi-dose vial 24,688 ±0 Chromatokid (talk | contribs) give the concentration in mg/mL as well as in units [rollback]
  9. (diff | hist) 02:29 ChinaPeptides 14,979 ±0 EndotoxinEd (talk | contribs) expand §Product range [rollback]

12 April 2026

  1. (diff | hist) 23:40 ISO 9001 4,278 ±0 CostPerMgCory (talk | contribs) split the compounding position from the manufacturing position [rollback]
  2. (diff | hist) m 19:46 Beta cell function 6,096 ±0 GsCouplingGil (talk | contribs) unpipe a link that did not need piping [rollback]
  3. (diff | hist) m 14:40 Orforglipron 5,647 ±0 TimelineTiernan (talk | contribs) add the discontinued indication with its date [rollback]
  4. (diff | hist) 14:22 Talk:Enteroendocrine L cell 611 +174 Chromatokid (talk | contribs) /* L-cell regeneration timescale — sourced? */ reply
  5. (diff | hist) 13:05 LEADER trial 4,799 ±0 SurvodutideSaff (talk | contribs) attribute the subgroup finding as exploratory [rollback]
  6. (diff | hist) 10:15 Talk:Enteroendocrine L cell 400 +225 CitationChaser (talk | contribs) /* L-cell regeneration timescale — sourced? */ new section
  7. (diff | hist) 09:36 USP General Chapter 85 5,180 ±0 Chromatokid (talk | contribs) state the titration endpoint and the reagent factor [rollback]
  8. (diff | hist) 08:40 Talk:Tirzepatide 959 +153 ReceptorRhoda (talk | contribs) /* Is "GIP-biased" the right term? */ reply
  9. (diff | hist) 08:24 Beyond-use date 23,171 ±0 A1c_Alder (talk | contribs) the vial strength in the example was inconsistent between two paragraphs [rollback]

11 April 2026

  1. (diff | hist) m b 20:53 Reconstitution calculator 8,662 ±0 CiteBot (talk | contribs) bot: add stub category [rollback]
  2. (diff | hist) 19:22 Sterile water for injection 4,738 ±0 DrTitration (talk | contribs) add a second worked example at a different vial strength [rollback]
  3. (diff | hist) 15:30 Chinese Peptide Company 15,513 ±0 Retention_Time_Rae (talk | contribs) expand §Distribution and dispatch [rollback]
  4. (diff | hist) 15:22 FLOW trial 4,583 ±0 DrTitration (talk | contribs) add the comparator arm — an event rate alone says nothing [rollback]
  5. (diff | hist) 15:20 Talk:Tirzepatide 748 +206 GsCouplingGil (talk | contribs) /* Is "GIP-biased" the right term? */ reply
  6. (diff | hist) 14:30 Shenzhen Hybio Pharmaceutical 17,496 ±0 BatchNumberBede (talk | contribs) ce, tighten prose [rollback]
  7. (diff | hist) 13:55 Talk:Peptide harm reduction 748 +94 BacWaterBarnaby (talk | contribs) /* Sterility is categorical */ reply
  8. (diff | hist) 13:20 Talk:Peptide aggregation 748 +104 Areapercent_Ayo (talk | contribs) /* RP-HPLC blind to aggregation */ reply
  9. (diff | hist) 12:45 Qingdao Saber Technology Pharmaceutical 14,592 +220 StateBoardStace (talk | contribs) add the note that self-published material is usable only for what it states about itself [rollback]
  10. (diff | hist) 11:50 Talk:Tirzepatide 537 +191 ReceptorRhoda (talk | contribs) /* Is "GIP-biased" the right term? */ new section
  11. (diff | hist) m 11:19 Preparative HPLC purification 4,882 ±0 CommaCarys (talk | contribs) expand §Scale-up [rollback]
  12. (diff | hist) m 11:03 Personal importation policy 4,121 ±0 LabelLibby (talk | contribs) rm the claim that the position has changed; no source supports it [rollback]
  13. (diff | hist) 10:20 Talk:Peptide harm reduction 537 +123 EndotoxinEd (talk | contribs) /* Sterility is categorical */ new section
  14. (diff | hist) 09:45 Talk:Peptide aggregation 537 +176 Chromatokid (talk | contribs) /* RP-HPLC blind to aggregation */ new section
  15. (diff | hist) 06:45 WuXi TIDES 16,434 ±0 DEXA_Dilys (talk | contribs) add the storage and handling guidance the organisation publishes [rollback]
  16. (diff | hist) 06:14 Bachem Holding (Suzhou) 15,124 ±0 EndotoxinEd (talk | contribs) add the reception tally with its period and count stated [rollback]
  17. (diff | hist) m b 04:09 Arcuate nucleus 5,251 ±0 CiteBot (talk | contribs) bot: update parent category chain [rollback]
  18. (diff | hist) m 02:43 Adverse effects of GLP-1 receptor agonists 5,791 ±0 Chromatokid (talk | contribs) add the interaction with the mechanism that explains it [rollback]
  19. (diff | hist) m 01:49 Peptide aggregation 5,516 ±0 ChromCleanupCass (talk | contribs) fix the anchor on an internal link [rollback]

10 April 2026

  1. (diff | hist) m 16:37 Triple agonist 4,269 ±0 AppendixAlva (talk | contribs) correct the dose ladder — the maintenance dose is not the maximum dose [rollback]
  2. (diff | hist) 14:35 Talk:Analytical method validation 748 +114 GradientGus (talk | contribs) /* Robustness and inter-laboratory disagreement */ reply
  3. (diff | hist) 11:00 Talk:Analytical method validation 537 +170 ResolutionRoo (talk | contribs) /* Robustness and inter-laboratory disagreement */ new section
  4. (diff | hist) 10:11 Dipeptidyl peptidase-4 7,022 ±0 BetaCellBoyd (talk | contribs) rm the causal claim about appetite — the cited work is associative [rollback]
  5. (diff | hist) m 08:30 Peptide supply chain 8,410 ±0 CrudePeptidePearl (talk | contribs) expand §The stages and what each can go wrong at [rollback]
  6. (diff | hist) 05:53 Contract development and manufacturing organisation 5,011 ±0 StopperingSteff (talk | contribs) fix hyphenation per PP:MOS [rollback]
  7. (diff | hist) 05:41 C-peptide 4,400 ±0 Chromatokid (talk | contribs) add the note that a single value out of range is not a finding [rollback]
  8. (diff | hist) m 01:50 Solid-phase peptide synthesis 5,359 ±0 FreightFenna (talk | contribs) add the collapse-temperature point, sourced [rollback]
  9. (diff | hist) 01:31 Glucose-dependent insulinotropic polypeptide 8,265 ±0 DPP4_Dagmar (talk | contribs) split overlong sentence [rollback]
  10. (diff | hist) m 01:24 Lyophilisation 28,679 ±0 CouplingCillian (talk | contribs) clarify that the cake appearance is an indicator, not a specification [rollback]

9 April 2026

  1. (diff | hist) m 22:00 Shanghai Sigma-Audley New Material Technology 15,579 ±0 BatchNumberBede (talk | contribs) expand §Operations and documentation practice [rollback]
  2. (diff | hist) m 21:48 Chain of custody 5,157 ±0 WeaselWordWim (talk | contribs) add category for certificates of analysis [rollback]
  3. (diff | hist) m b 19:06 GenScript Peptides 17,833 +220 CiteBot (talk | contribs) bot: add supplier category [rollback]
  4. (diff | hist) m b 16:20 Prior authorisation 4,216 ±0 CategoryBot (talk | contribs) bot: sort category members [rollback]
  5. (diff | hist) 16:20 Survodutide 5,445 ±0 LiraLotte (talk | contribs) expand §Status and material sold under the name [rollback]
  6. (diff | hist) 14:53 Placebo-adjusted effect 4,805 ±0 RfC_Rasmus (talk | contribs) the percentage quoted was placebo-adjusted; label it [rollback]
  7. (diff | hist) 14:20 Talk:Gastric emptying 748 +203 ToleranceTove (talk | contribs) /* Tachyphylaxis wording */ reply